40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease

Informazioni relative al progetto

BRIGHT

ID dell’accordo di sovvenzione: 867873

DOI

10.3030/867873

Progetto chiuso

Data della firma CE 26 Aprile 2019

Data di avvio 1 Maggio 2019

Data di completamento 30 Settembre 2019

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

OPTOCEUTICS APS
Denmark

Periodic Reporting for period 1 - BRIGHT (40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease)

Periodo di rendicontazione: 2019-05-01 al 2019-09-30

Sintesi del contesto e degli obiettivi generali del progetto

One of the major public health challenges worldwide is the rapidly growing number of people with dementia. More than 50 million people worldwide are living with dementia and about 70% of those are diagnosed with Alzheimer’s disease. Although a global burden – equivalent to 1% of the world's GDP – AD is particularly critical in the EU, where over 10.5 million patients live with dementia.
BRIGHT aims to develop 40 Hz flickering light therapy using novel invisible spectral flicker (ISF) that can induce brainwaves in AD patients and potentially improve cognition and potentially slow the disease progression. The light is combined in a way that the flickering is non-perceptible and thus not hindering vision or causing discomfort. The primary objective of the project is to validate the need for such a treatment, and establish the necessary partners for the clinical evaluation.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

During the feasibility study of Phase 1 we gathered tremendous amount of information and uncovered valuable knowledge and understanding, some of which are the following:
- User requirements addressed by subsequent new design features
- Market analysis that identified the most interesting market segment, in regards to effect, willingness and size. This sharpens our eye and approach onwards in regards to product development, strategy and IPR
- Effective and detailed national go-to-market strategy and business model to address the market segment, including supply and sales setup
- Strong partnership with key clinical partners and pilot test participants

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

With the work done in SMEi Phase 1, it is now possible to move directly forward to clinical tests, with a device at that is validated among the users, designed and optimised for regulatory approval.
Furthermore a clear plan of the implementations of the 40 Hz neuromodulation light in a business setting is prepared - Ultimately leading to potentially better health and life among the population.

Optoceutics Logo